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Commentary
Adding Mirabegron to Solifenacin to
Treat Overactive Bladder Has Little
Impact on Postvoid Residual Volume
or Urinary Retention Risk
Marcus J. Drake, Scott MacDiarmid, Salman Al-Shukri, Jack Barkin, Aino Fianu-Jonasson,
Sender Herschorn, Moses Huang, Matthias Stoelzel, and Emad Siddiqui
Urinary retention is a complex and important uro-logic health issue that describes the inability tocompletely empty the bladder.1 The sudden in-
ability to void is termed acute urinary retention, which is
usually accompanied by pain and severe urgency, and can
have serious consequences if untreated.2 Occasionally, acute
urinary retention may be precipitated by an event such as
infection or medication; thus, the definition is further sub-
divided into precipitated or spontaneous.1 Chronic urinary
retention describes the persistent inability to completely
empty the bladder and is usually painless and impercep-
tible to the patient.3
The majority of epidemiologic data on urinary reten-
tion relates to acute urinary retention in older male pa-
tients due to its association with benign prostatic
enlargement (BPE), and because clinically significant symp-
toms requiring medical attention are more likely to be re-
ported than chronic urinary retention, which is often
unperceived by the patient. In men aged 40–83 years, the
overall incidence of acute urinary retention is 4.5-6.8 per
1000 men per year,4,5 many times higher than in women
(7 per 100,000 general population per year).6 Incidence also
increases with age, affecting eight times as many men aged
70-79 years than those aged 40-49 years.2 The etiology of
acute urinary retention can be classified into 3 catego-
ries: mechanical or dynamic obstruction (eg, BPE or drugs
that increase smooth muscle tone), impaired neurologic co-
ordination of voiding (eg, pelvic surgery or spinal injury),
and bladder overdistension (eg, drugs or excessive alcohol
that inhibit bladder contractility).7,8
Consequences of urinary retention include impaired
quality of life, deterioration in the upper urinary tract func-
tion due to chronic excessive bladder pressure, and recur-
rent urinary tract infections and bladder calculi, which result
from stagnated urine.9 Management of acute urinary re-
tention usually requires catheterization to empty the bladder
and to alleviate symptoms.8
In patients with overactive bladder (OAB), the Ameri-
can Urological Association and the Society of Urodynamics,
Female Pelvic Medicine, & Urogenital Reconstruction rec-
ommend the measurement of postvoid residual (PVR) urine
volume via catheterization or bladder ultrasound scan, where
there is a history of or risk factors associated with urinary
retention (ie, voiding symptoms, history of incontinence
or prostatic surgery, and neurologic diagnoses).10 A PVR
volume of <50 and <100 mL signifies adequate bladder emp-
tying in the general population and the elderly popula-
tion, respectively; a PVR volume of >200 mL is considered
abnormal.11 Unfortunately, PVR volume is associated with
large intrapatient variability, and only extreme values
(>500 mL) appear to be predictive of acute urinary
retention.6 In clinical practice, patients with suspected in-
complete bladder emptying are managed according to the
severity of the PVR volume and the suspected or identi-
fied etiology. For example, at the Department of Urology,
Karolinska University Hospital-Huddinge, Sweden, before
being discharged from the hospital, inpatients with, or sus-
pected of, impaired bladder emptying undergo a bladder
ultrasound scan immediately after emptying their bladder
and are managed according to 1 of 4 categories of PVR
volume: (1) 100-150 mL, follow-up bladder scan after
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3 hours; (2) 150-300 mL, follow-up bladder scan after 2
hours; (3) 300-400 mL, follow-up bladder scan after 1 hour;
and (4) >400 mL, bladder to be emptied using clean in-
termittent catheterization or a permanent catheter accord-
ing to the physician (personal communication between Dr.
Aino Fianu-Jonasson and Dr. Tareq Alsaody, November
2016).
In clinical trials, it is important to identify potential dose-
related increases or clinically relevant changes in the PVR
volume following treatment with medications that have the
potential to increase the risk of urinary retention. In the case
of OAB, pharmacotherapies used to inhibit bladder con-
tractility or to induce bladder relaxation during the storage
phase could, in theory, potentially increase the risk of urinary
retention. These include antimuscarinics (eg, solifenacin and
tolterodine), β3-adrenoceptor agonist (mirabegron), and the
intravesical therapy onabotulinumtoxinA.7,12 Patients most
at risk may include the elderly, who are more likely to have
reduced bladder contractility, pre-existing comorbidities, and
concomitant medications that reinforce detrusor relax-
ation; others at risk include men with pre-existing bladder
outlet obstruction and patients with a history of excessive
PVR volumes.6,7 The rate of acute urinary retention re-
ported with OAB medications varies from ~8% with
onabotulinumtoxinA12 to less than 1% with antimuscarinics
and mirabegron13; nevertheless, there is still a perception
among physicians of an increased risk with antimuscarinics
in male patients, which is often attributed to their mode of
action.14
In 12-week placebo-controlled trials, mirabegron and
tolterodine extended release (ER) were associated with
placebo-like changes in the PVR volume (−0.9 mL
[mirabegron 50 mg], −1.6 mL [placebo], and +0.1 mL
[tolterodine ER 4 mg]), and the incidence of urinary reten-
tion was negligible (0.1% [mirabegron 50 mg], 0.6%
[tolterodine ER 4 mg], and 0.5% [placebo]).13 In high-risk
cohorts such as male OAB patients with obstructive symp-
toms, urodynamic parameters are unaffected and acute urinary
retention remains low following monotherapy or combina-
tion treatment. In 127 men with OAB and bladder outlet
obstruction, the maximum urine flow rate (Qmax) and de-
trusor pressure at Qmax (Pdet·Qmax) were comparable between
patients treated with mirabegron 50 mg and placebo. The
change from baseline to end of treatment (EoT) inQmax was
0.07 and −0.33 mL/s, and the changes in Pdet·Qmax were −3.03
and 2.92 cmH2O with mirabegron 50 mg and placebo, re-
spectively. The increase in PVR volume was higher follow-
ing treatment with mirabegron 50 mg vs placebo (~18 mL
vs 0.5 mL) but remained clinically insignificant, as re-
flected by the solitary case of acute urinary retention in the
placebo group.15 Similar low rates of acute urinary reten-
tion (<1.0%) have been reported following a combination
of mirabegron or antimuscarinic plus the alpha-blocker
tamsulosin in male patients with lower urinary tract
symptoms.16,17 Treatment differences in urodynamic param-
eters have been reported in female OAB patients (n = 40)
treated with solifenacin 5 mg or mirabegron 50 mg for 12
weeks, who had a PVR volume of <100 mL at baseline. Al-
though similar improvements in storage-phase parameters
such as bladder capacity and detrusor overactivity were ob-
served, solifenacin had a detrimental effect on voiding-
phase parameters compared tomirabegron. TheQmax, opening
detrusor pressure (Pdet·open), and Pdet·Qmax decreased signifi-
cantly, whereas the PVR volume increased significantly with
solifenacin 5 mg (+3.28 mL, P = .0139). In contrast, Qmax,
Pdet·open, and Pdet·Qmax all increased without significance and
the PVR volume was moderately reduced without signifi-
cance with mirabegron 50 mg (−1.13 mL).18 Despite the sta-
tistically significant changes in voiding parameters with
solifenacin, the increase in the PVR volume was not clini-
cally significant. The study was limited by the small patient
population but illustrated the opposing actions of both drug
classes on voiding function and the propensity to retain urine.
However, these opposing actions on voiding mechanics do
not appear to translate into clinically meaningful differ-
ences at 12 weeks or longer. After 12 months of treatment
with mirabegron 50 mg or tolterodine ER 4 mg, the rate of
urinary retention remained low (n = 1 [0.1%] mirabegron
50 mg vs n = 3 [0.4%] tolterodine ER 4 mg), and one case
of acute urinary retention was reported with tolterodine,
which required discontinuation of the drug.19
The distinct mechanisms of action that distinguish
mirabegron from antimuscarinics suggest that their use in
combination could have an additive or synergistic inhibi-
tory effect on bladder contractility and urinary retention
risk. Herein we report PVR volumes and urinary reten-
tion rates in OAB patients treated with a combination of
an antimuscarinic (solifenacin) and mirabegron in the
BESIDE study (NCT01908829).
The BESIDE study investigated the efficacy and safety
of add-on mirabegron 50 mg to solifenacin 5 mg (combi-
nation) vs solifenacin monotherapy (5 or 10 mg) for 12
weeks, in refractory incontinent OAB patients after an
initial 4-week dose of solifenacin 5 mg. Combination treat-
ment provided greater improvement in OAB symptoms and
patient-reported outcomes vs solifenacin monotherapy, and
was well-tolerated.20,21 The PVR volume was assessed by
bladder ultrasound scan at each visit and was summarized
according to absolute change and shift to 1 of 3 catego-
ries (≥0 to <150 mL, ≥150 to <300 mL, ≥300 mL) from base-
line to EoT. Increases in the PVR volume from a baseline
value of <150 mL to a PVR volume of >250 mL were
queried for clinical significance; treatment-emergent adverse
events (TEAEs) for urinary retention were based on spon-
taneous reporting using a predefined list of preferred and
lower-level terms.20 The mean baseline PVR volume ranged
from 23 to 26 mL across the treatment groups. Patients
with a PVR volume of >150 mL were excluded from the
study. At EoT, small, clinically insignificant increases in
the PVR volume were observed with combination treat-
ment (5.5 mL), solifenacin 5 mg (3.0 mL), and solifenacin
10 mg (7.4 mL). Approximately 97% or more of patients
in any treatment group had no shift in the PVR volume
to a higher category from baseline to EoT (Fig. 1). In-
creased residual urine volume was reported as a TEAE in
6 patients (combination treatment, n = 2 [0.3%]; solifenacin
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5 mg, n = 2 [0.3%]; and solifenacin 10 mg, n = 2 [0.3%]),
and urinary retention was reported as a TEAE in 8 pa-
tients (combination, n = 2 [0.3%]; solifenacin 5 mg, n = 1
[0.1%]; solifenacin 10 mg, n = 5 [0.7%]). Two patients in
the solifenacin 10 mg group discontinued treatment due
to urinary retention, but there were no cases of acute urinary
retention or patients requiring catheterization in any treat-
ment group.
The magnitude of the change in the PVR volume and
rates of urinary retention after 12 weeks in the BESIDE
study is consistent those in other 12-week studies that have
investigated various doses of mirabegron (25 or 50 mg) and
solifenacin (2.5, 5.0, or 10.0 mg) in combination.22-24 In
a phase II, dose-ranging study including 1306 OAB pa-
tients, the highest reported mean increase in PVR volume
was 13.9 mL in the solifenacin 10 mg-mirabegron 50 mg
group; 1 case of acute urinary retention was reported in the
solifenacin 2.5 mg-mirabegron 25 mg group.22 In a phase
III study in 223 Japanese OAB patients, the highest mean
increase in PVR volume was 8.0 mL in the solifenacin 5 mg-
mirabegron 25 mg group, and there were no cases of urinary
retention.23 In the SYNERGY study (NCT01972841),
which compared solifenacin 5 mg-mirabegron 25 mg or
50 mg vs solifenacin or mirabegron monotherapy or placebo
in 3527 OAB patients, the highest change in the mean
PVR volume was 11 mL in the solifenacin 5 mg-mirabegron
50 mg group; there were 4 cases of urinary retention re-
quiring catheterization (solifenacin 5 mg-mirabegron 25 mg,
n = 2, and solifenacin 5 mg-mirabegron 50 mg, n = 2),
which was considered acute urinary retention in 1 patient
treated with solifenacin 5 mg-mirabegron 50 mg.24
The BESIDE study suggests that combining 2 distinct
classes of oral pharmacotherapy (antimuscarinic and β3-
adrenoceptor agonist) to treat OAB has a negligible effect
on the PVR volume and urinary retention risk. The
coadministration of solifenacin 5 mg and mirabegron 50 mg
may be a reasonable alternative to a dose escalation to
solifenacin 10 mg, without compromising bladder contrac-
tility during the voiding phase, as demonstrated by the
absence of clinically relevant changes in the PVR volume.
Study limitations included the relatively small male cohort
(approximately 25% of the overall population), which is
an inherent problem in OAB trials, and the low propor-
tion of patients, ~ 30% and ~8%, respectively, over the age
of 65 and 75 years, who are potentially more susceptible
to urinary retention or increases in PVR volume.
In clinical practice, the routine assessment of residual urine
is recommended in high-risk cohorts such as elderly men (>75
years) with BPE, patients with a history of elevated PVR
volumes (>200 mL), and patients with OAB receiving oral
pharmacotherapy as monotherapy or combination therapy
who develop voiding symptoms. Further studies are recom-
mended to improve our understanding of the relationship
between PVR volume and urinary retention, and to explore
predictive factors in the male and female OAB popula-
tion. It is important to recognize that the inclusion and ex-
clusion criteria employed in phase III clinical trials minimize
the number of patients with a history or high risk of urinary
retention. Observational and noninterventional studies are
more reflective of real-life clinical practice and are recom-
mended as a means of assessing the efficacy and safety of OAB
medications in higher-risk cohorts.
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Figure 1. Shift in PVR volume from baseline to EoT. *Baseline ≥0 to <150 L increased to ≥150 to <300 mL or to ≥300 mL,
or baseline ≥150 to <300 mL increased to ≥300 mL; †baseline ≥150 to <300 mL decreased to ≥0 to <150 mL or base-
line ≥300 mL decreased to ≥150 to <300 mL or decreased to ≥0 to <150 mL. EoT, end of treatment. (Color version avail-
able online.)
ARTICLE IN PRESS
3UROLOGY ■■ (■■), 2017
Acknowledgment. The authors thank Stuart Murray, MSc (En-
vision Scientific Solutions), for medical writing assistance and
for assistance in the preparation of the initial and final drafts of
the manuscript.
References
1. Kaplan S, Wein A, Staskin R, Roehrborn C, Steers W. Urinary re-
tention and post-void residual urine in men: separating truth from
tradition. J Urol. 2008;180:47-54.
2. Choong S, Emberton M. Acute urinary retention. BJU Int.
2000;85:186-201.
3. Deane AM, Worth PH. Female chronic urinary retention. Br J Urol.
1985;57:24-26.
4. Meigs JB, Barry MJ, Giovannucci E, Rimm EB, Stampfer MJ, Kawachi
I. Incidence rates and risk factors for acute urinary retention: the health
professionals followup study. J Urol. 1999;162:376-382.
5. Jacobsen SJ, Jacobson DJ, Girman CJ, et al. Natural history of pros-
tatism: risk factors for acute urinary retention. J Urol. 1997;158:481-
487.
6. Klarskov P, Andersen JT, Asmussen CF, et al. Acute urinary reten-
tion in women: a prospective study of 18 consecutive cases. Scand J
Urol Nephrol. 1987;21:29-31.
7. Verhamme K, Sturkenboom M, Stricker B, Bosch R. Drug-induced
urinary retention: incidence, management and prevention. Drug Saf.
2008;31:373-388.
8. Kalejaiye O, Speakman M. Management of acute and chronic urinary
retention in men. Eur Urol. 2009;8(suppl):523-529.
9. Adelowo AO, Hacker MR, Merport Modest A, Elkadry EA. Do symp-
toms of voiding dysfunction predict urinary retention? Female Pelvic
Med Reconstr Surg. 2012;18:344-347.
10. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treat-
ment of overactive bladder (non-neurogenic) in adults: AUA/
SUFU guideline. J Urol. 2012;188(suppl 6):2455-2463.
11. Kelly CE. Evaluation of voiding dysfunction and measurement of
bladder volume. Rev Urol. 2004;6(suppl 1):S32-S37.
12. Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botu-
linum toxin A injections for idiopathic detrusor overactivity: risk
factors and influence on treatment outcome. Eur Urol. 2010;58:919-
926.
13. Nitti V, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treat-
ment of overactive bladder: a prespecified pooled efficacy analysis and
pooled safety analysis of three randomised, double-blind, placebo-
controlled, phase III studies. Int J Clin Pract. 2013;67:619-632.
14. Oelke M, Speakman M, Desgrandchamps F, Mamoulakis C.
Acute urinary retention rates in the general male population and
in adult men with lower urinary tract symptoms participating in
pharmacotherapy trials—a literature review. Urology. 2015;86:
654-665.
15. Nitti V, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin
NE. Urodynamics and safety of the β3-adrenoceptor agonist mirabegron
in males with lower urinary tract symptoms and bladder outlet ob-
struction. J Urol. 2013;190:1320-1327.
16. van Kerrebroeck P, Chapple CR, Drogendijk T, et al. Combina-
tion therapy with solifenacin and tamsulosin oral controlled absorp-
tion system in a single tablet for lower urinary tract symptoms in men:
efficacy and safety results from the randomised controlled NEPTUNE
trial. Eur Urol. 2013;64:1003-1012.
17. Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka
Y. A randomized controlled study of the efficacy of tamsulosin
monotherapy and its combination with mirabegron for overactive
bladder induced by benign prostatic obstruction. J Urol. 2015;193:921-
926.
18. Scaldazza CV, Morosetti C. Comparison of therapeutic efficacy and
urodynamic findings of solifenacin succinate versus mirabegron in
women with overactive bladder syndrome: results of a randomized
controlled study. Urol Int. 2016;97:325-329.
19. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-
blind, active-controlled phase 3 study to assess 12-month safety and
efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive
bladder. Eur Urol. 2013;63:296-305.
20. Drake MJ, Chapple C, Esen AA, et al. Efficacy and safety of
mirabegron add-on therapy to solifenacin in incontinent overac-
tive bladder patients with an inadequate response to initial 4-week
solifenacin monotherapy: a randomised double-blind multicentre phase
3B study (BESIDE). Eur Urol. 2016;70:136-145.
21. MacDiarmid S, Al-Shukri S, Barkin J, et al. Mirabegron as add-on
treatment to solifenacin in patients with incontinent overactive
bladder and an inadequate response to solifenacin monotherapy: re-
sponder analyses and patient-reported outcomes from the BESIDE
study. J Urol. 2016;196:809-818.
22. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with
mirabegron and solifenacin in patients with overactive bladder: ef-
ficacy and safety results from a randomised, double-blind, dose-
ranging, phase 2 study (Symphony). Eur Urol. 2015;67:577-588.
23. Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of
mirabegron as add-on therapy in patients with overactive bladder
treated with solifenacin: a post-marketing, open-label study in Japan
(MILAI study). BJU Int. 2015;116:612-622.
24. Herschorn S, Chapple C, Abrams P, et al. Efficacy and safety of com-
binations of mirabegron and solifenacin compared with monotherapy
and placebo in patients with overactive bladder (SYNERGY study).
BJU Int. 2017; accepted for publication.
ARTICLE IN PRESS
4 UROLOGY ■■ (■■), 2017
